Immuron Ltd IMRN shares are trading higher Monday after the company announced the FDA removed the clinical hold on its new Campylobacter ETEC Therapeutic IND application.
What Happened: The U.S. Naval Medical Research Center (NMRC) received approval from the FDA to proceed with the clinical trials of its oral therapeutic developed in collaboration with Immuron, which targets Campylobacter and ETEC.
The product will be tested utilizing two controlled human infection-model clinical trials. One trial will focus on protecting against ETEC infections and the other trial will focus on moderate to severe campylobacteriosis.
Immuron is a biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases. A preventative treatment that protects against enteric diseases is a high priority objective for the U.S. military.
See Also: WHO Ends Global Emergency Status for COVID-19 3 Years After Declaration, CDC Director Resigns
IMRN Price Action: Immuron shares were up 61% at $3.03 at the time of publication, according to Benzinga Pro.
This illustration was generated using artificial intelligence via MidJourney.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
